drugset / Trial / NCT01127321
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
Timeline
- Start
- 2010-05
- Primary completion
- 2012-07
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI-570 | Monoclonal antibody | 0.03 mg | Subcutaneous |
| Subject | MEDI-570 | Monoclonal antibody | 0.1 mg | Subcutaneous |
| Subject | MEDI-570 | Monoclonal antibody | 0.3 mg | Subcutaneous |
| Subject | MEDI-570 | Monoclonal antibody | 1 mg | Subcutaneous |